pharmaphorum Podcast

Graphite Digital’s study of 100 senior pharma leaders across Europe and North America earlier this year investigated organisations’ attitudes towards hot industry topics, including – of course – AI, omnichannel, and globalisation.

So it was pharmaphorum web editor Nicole Raleigh welcomed Graphite Digital’s CEO, Rob Verheul, to the podcast as guest, in order to discuss digital strategy and the Salesforce-Veeva split.

Verheul also co...

Last week in Berlin the Frontiers Health Conference celebrated its 10th Anniversary with a whirlwind two days of panels and presentations from founders, executives, and patients across the healthcare ecosystem.

Whilst there, pharmaphorum editor-in-chief Jonah Comstock and web editor Nicole Raleigh, together with Frontiers Health co-host Jessica DaMassa, met up on-site immediately after the event came to a close in order to discuss ...

Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders.

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, a membership organisation where big pharma companie...

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pricing. This was followed by similar announcements from AstraZeneca and Merck. But are these deals substantive policy or PR sleight of hand?

In today’s episode of the pharmaphorum podcast, host Jonah Comstock invites Hogan Lovells Partner...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political.

In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy, and grandson of FDR, as well as Advisory Board Member for Pluri Inc, discusses regulatory bottlenecks and their stalling effect on cell-based therapi...

Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding tissue are few. And this is where targeted radiotherapeutics come in.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Marc Hedrick, president and CEO of Plus Therapeutics, a clinical stage pharmaceutical compan...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company building one of the world’s leading AI infrastructure companies.

Burkov discusses the deployment of AI and cloud-native infrastructure for improving the speed and indeed quality of drug development, as well as why access to compute not enough and how GenAI is helping pharma teams integ...

Bayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM, taking that relationship, and Bayer’s connected platform journey, to the next level.

In order to discuss this migration further, pharmaphorum spoke with Alexander Alex, head of Veeva Platform at Bayer, and Florian Schnappauf, vice president of enterprise commercial strategy at Veeva.

...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-small cell lung cancer (NSCLC), tumour shrinkage observed by investigator review - Boehringer Ingelheim is racing to expand its label.

As the company reported new data at the Congress from the phase 1b Beamion LUNG-1 study, underpinning the approval of zongertinib (Hernexeos) as a seco...

Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump administration this year.

Tune into today’s podcast for an exploration of the potential scenarios Masia mused might arise, as well as his insights on the 340B Program, PBMs, and risk-based contracts.

You can listen to episode 210 of the ...

In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione.

Ascione - a serial entrepreneur & thought leader in health innovation and digital health, global executive, CEO and founder of Healthware Group, and President of Health Innovation at EVERSANA – talks about his favourite memory from Frontiers Heal...

As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space.

Mack discusses the company’s progress in this field, and explores where next in terms of the unmet needs of Parkinson’s disease and the potential of this specific area ...

As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has had a front-row seat to the events evolution over the last decade.

In this episode of the pharmaphorum podcast’s special Frontiers Health anniversary series, DaMassa joins Deep Dive editor, Eloise McLennan, for a behind-the-scenes look at what it takes to run the show – both on and off...

Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements.

In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the only way organisations can solve all three of those problems is by first solving dat...

The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed President and COO of Fujifilm Biosciences, a company previously known as Fujifilm Irvine Sci...

This year marks the 10th anniversary of Frontiers Health.

In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida, founder of i-Expand, a commercial strategy firm focused on assisting Health Tech and Deeptech companies grow and monetise.

Fernández Hermida shares her favourite memory from the conference’s past decade, and discusses commer...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally.

Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’s required by way of a culture shift more generally, as well as speaking to the c...

This year marks the 10th anniversary of Frontiers Health.

In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with founder, director, and global health advisor at D-Health Consulting, Roberta Sarno. Sarno is also director of the APAC Liver Disease Alliance, and consultant on digital health APAC policy at the American Telemedicine Association, as well as advisor to the Asia Pacific Medical...

This year marks the 10th anniversary of Frontiers Health.

In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk.

Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that.

Explore this Frontiers Health conversation and others - and find out how to attend ...